April 2026 Interim Peptide Index Update

Why we're publishing this between quarterly reports

The Q2 2026 Peptide Index shipped on 21 April 2026 covering Q1 2026 market dynamics. Within 24 hours of that publication, three public events materially shifted the category:

1. Bryan Johnson (Blueprint) posted a complete four-week CJC-1295 DAC + tirzepatide self-experiment protocol with a full measurement stack. 188k views.
2. Amazon / One Medical launched a consumer GLP-1 subscription at $149/month oral / $299/month injectable.
3. Invest Like the Best published the Alex Karnal episode explicitly framing GLP-1s and peptides as "the start of a once-in-a-lifetime, trillion-dollar revolution in public health" and dedicating a chapter to "Citizen Pharmacology and the Peptide Movement."

None of these were anticipated by the Q2 report's "what to watch" section. Taken together, they accelerate the mainstreaming trajectory we described in Q2 by roughly one quarter. This interim update captures that shift without waiting until the Q3 publication in July.

This is a new cadence the Pepwizard editors are trialling: a short interim supplement between quarterly indices when a material event warrants it. Our aim is to produce no more than one interim per quarter.

Three forces reshaping the April 2026 category

1. Data-first biohacking enters the mainstream (Bryan Johnson)

Johnson's protocol post (source ↗) opens with the sentence "Everyone's injecting peptides. Almost no one is measuring what they actually do." That frame — the data gap between peptide use and peptide measurement — is the clearest statement yet of the structural problem the sub-culture has created for itself.

What makes this different from previous biohacker peptide posts:

• Hypothesis-driven. Johnson frames the stack as an explicit test of the hypothesis that CJC-1295 DAC's glucose-blunting vector and tirzepatide's HR-raising vector cancel.
• Fully instrumented. Weekly bloods across 11 analytes, continuous CGM, continuous core body temp via eCelsius capsule, 24/7 HRV. This is institutional-grade measurement applied to a consumer self-experiment.
• Publicly committed. The protocol is published in advance, with commitments to publish results weekly.

Expected knock-on effects:

• A measurement-first frame becomes the higher-status posture inside peptide X.
• Search demand for private bloodwork services that panel IGF-1, HOMA-IR, and cortisol extensions will rise.
• Vendors that publish protocols alongside compounds — not just reconstitution guidance — gain an edge over those that don't.

We've published two new pieces grounded in this post: the "Everyone injects, no one measures" explainer and a Johnson stack companion page.

2. Amazon at $149/month resets the GLP-1 price ceiling

Amazon's One Medical GLP-1 subscription (source: @PeptideList, Apr 21 2026 ↗) is the lowest at-scale consumer price the GLP-1 category has seen. For context:

Channel	Typical monthly price	Notes
UK private telehealth (Wegovy / Mounjaro)	£140–220	Prescribed; clinician-supervised
US commercial payer (branded)	$600–1,350	Pre-rebate
US compounded telehealth (pre-Amazon)	$199–299	Compounded semaglutide equivalent
Amazon / One Medical oral (Apr 2026)	$149	Oral formulation
Amazon / One Medical injectable	$299	Weekly injectable

Second-order implications:

• Tier 2 telehealth vendors face direct pricing pressure. Existing $199–299 compounded-semaglutide providers have to compete on clinical service quality or sub-$149 with thinner margins.
• Tier 1 research vendors lose the "only channel available" moat. If a molecule is widely available via licensed compounding at $149, the premium commanded for the research-channel version narrows.
• Tier 3 cosmetic-supplement vendors are unaffected. Their molecules (topical GHK-Cu, oral collagen) don't overlap with the GLP-1 re-pricing.

Our read: expect median £/mg for tirzepatide and semaglutide in the Tier 1 research channel to soften another 10–18% through Q3 2026 as the Amazon price ceiling exerts downward pressure. The full analysis is in the Amazon/FDA peptide mainstreaming explainer.

3. Citizen pharmacology enters institutional-investor vocabulary (Karnal)

Patrick O'Shaughnessy's Invest Like the Best episode with Alex Karnal (source ↗) is the first top-tier business podcast to treat peptides as a category rather than a sub-story inside GLP-1. The episode's chapter 1:14:40 is titled "Citizen Pharmacology and the Peptide Movement."

Why this matters for the vendor landscape:

• Institutional capital noticing a category is a leading indicator of consolidation. Expect 2–3 of the better-capitalised Tier 1 research vendors to raise equity or be acquired in the next 18 months.
• Distribution-as-moat thesis validates Pepwizard's comparison-engine positioning. Karnal's repeat frame — "we already have the medicines; distribution is what's missing" — is the thesis behind every price-comparison or telehealth aggregator that serves a fragmented supply side.
• Karnal-style framing gives mainstream media a vocabulary for peptides. Expect "citizen pharmacology" to appear in Bloomberg, WSJ, and FT coverage by Q3.

Full companion page: Invest Like the Best × Alex Karnal.

Updated "what to watch" — the next 90 days

Superseding the Q2 report's outlook:

• Amazon / One Medical GLP-1 sign-up rate — if public metrics leak, it recalibrates every competing telehealth vendor's pricing.
• Weekly Bryan Johnson protocol updates — his measurement data, published weekly, becomes a citable public dataset on the DAC + tirzepatide stack.
• July 2026 FDA vote on BPC-157 — unchanged; still the single largest regulatory event on the calendar.
• Secondary 12+ peptide deregulation list — currently under review at the FDA Pharmacy Compounding Advisory Committee. List not yet published; we will update.
• Orforglipron approval timing — Eli Lilly filed NDA in January 2026; FDA decision anticipated H2 2026.

Price drift since the Q2 report

Changes since 21 April 2026 (24 hours of drift, largely unchanged):

• Median Tirzepatide £/mg: broadly stable, with one Tier 1 vendor (Apollo) opening a 15% promotional window.
• BPC-157 UK-domestic floor: £6.9/mg, unchanged.
• GHK-Cu topical category: mainstream retail promotions continuing; no material new entrants.
• Retatrutide street floor: £22/mg, unchanged.

Full live numbers at the master price matrix.

Methodology

Same as the Q2 2026 Peptide Index. Pricing from Pepwizard's daily vendor scrape, normalised to £/mg at current FX rates (GBP 1, USD 0.79, EUR 0.87 as of 2026-04-22). Sources cited inline. Q3 2026 proper will publish in early July.